About Avai Bio Inc
- Industry: Technology
- Exchange: OTC MARKETS
- Country: US
- Website: https://avaibio.com
Frequently Asked Questions
What is the 52-week range for AVAI?
The 52-week high is $0.8 and the 52-week low is $0.1012.
What is the P/E ratio for AVAI?
The P/E ratio data is currently unavailable.
What is the dividend yield for AVAI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -220.34%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -490.49%.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Latest AVAI News
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its joint venture partner Austrianova, today announced the successful encapsulation of GMP-quality Klotho-producing cells in the joint venture’s signature technology, Cell-in-a-Box® capsules. After the successful completion of comprehensive adventitious ag
Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference
LAS VEGAS, NEVADA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), together with joint venture partner Austrianova, today announced that Prof. Walter H. Günzburg presented the companies’ encapsulated-cell approach to sustained α-Klotho delivery at the Second Annual Klotho Conference, held September 18–19 in Miami. The 20-minute talk outlined how Austrianova’s Cell-in-a-Box® technology is being applied through Klothonova, the 50/50 joint venture formed b
Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy
LAS VEGAS, NV, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced, together with its joint venture partner and global biotechnology company Austrianova, the successful completion of comprehensive adventitious agent and viral testing of its GMP Master Cell Bank (MCB), from which its Working Cell Bank (WCB) was